| Phenix City Health Care, Inc | |
| 3900 Lakewood Drive, Phenix City, Alabama 36867 | |
| (334) 298-8247 | |
| Name | Phenix City Health Care, Inc |
|---|---|
| Location | 3900 Lakewood Drive, Phenix City, Alabama |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 86 |
| Occupancy Rate | 73.37% |
| Medicare ID (CCN) | 015331 |
| Legal Business Name | Phenix City Health Care, Inc. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1750469862 |
| Organization Name | PHENIX CITY HEALTH CARE, LLC |
| Address | 3900 Lakewood Dr, Phenix City, AL 36867 |
| Phone Number | 334-298-8247 |
News Archive
No one wants to hear the words, "you have colon cancer." For patients diagnosed with an advanced form of the disease, these words can be particularly devastating. The five-year survival rate can be a little as 6 percent. The top-of-mind question becomes, "Which treatment or clinical trial will work for me?"
Ahead of World TB Day, US Food and Drug Administration Commissioner Margaret Hamburg helped public and private sector partners launch a new collaboration to significantly accelerate the development of combination treatments for tuberculosis — and replace an almost 50-year-old drug regimen. Created by the Global Alliance for TB Drug Development, the Critical Path Institute, and the Bill & Melinda Gates Foundation, the initiative could potentially reduce the time it takes to introduce new combination TB treatments from as much as a quarter century to as few as six years.
Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company's semiconductor-based synthetic gene manufacturing process.
The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention, and cure research.
› Verified 9 days ago
| NPI Number | 1942921978 |
| Organization Name | ARABELLA HEALTH AND WELLNESS OF PHENIX CITY LLC |
| Doing Business As | EAST VILLAGE NURSING AND REHAB OPCO LLC |
| Address | 3900 Lakewood Dr, Phenix City, AL 36867 |
| Phone Number | 334-298-8247 |
News Archive
No one wants to hear the words, "you have colon cancer." For patients diagnosed with an advanced form of the disease, these words can be particularly devastating. The five-year survival rate can be a little as 6 percent. The top-of-mind question becomes, "Which treatment or clinical trial will work for me?"
Ahead of World TB Day, US Food and Drug Administration Commissioner Margaret Hamburg helped public and private sector partners launch a new collaboration to significantly accelerate the development of combination treatments for tuberculosis — and replace an almost 50-year-old drug regimen. Created by the Global Alliance for TB Drug Development, the Critical Path Institute, and the Bill & Melinda Gates Foundation, the initiative could potentially reduce the time it takes to introduce new combination TB treatments from as much as a quarter century to as few as six years.
Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company's semiconductor-based synthetic gene manufacturing process.
The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention, and cure research.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
No one wants to hear the words, "you have colon cancer." For patients diagnosed with an advanced form of the disease, these words can be particularly devastating. The five-year survival rate can be a little as 6 percent. The top-of-mind question becomes, "Which treatment or clinical trial will work for me?"
Ahead of World TB Day, US Food and Drug Administration Commissioner Margaret Hamburg helped public and private sector partners launch a new collaboration to significantly accelerate the development of combination treatments for tuberculosis — and replace an almost 50-year-old drug regimen. Created by the Global Alliance for TB Drug Development, the Critical Path Institute, and the Bill & Melinda Gates Foundation, the initiative could potentially reduce the time it takes to introduce new combination TB treatments from as much as a quarter century to as few as six years.
Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company's semiconductor-based synthetic gene manufacturing process.
The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention, and cure research.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 18.1 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.12 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 62.71 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.73 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.26 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 8.95 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.16 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.3 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 10.99 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.53 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.26 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 10.7 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 1.48 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.34 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 45.41 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 83.78 | 82.93 |
News Archive
No one wants to hear the words, "you have colon cancer." For patients diagnosed with an advanced form of the disease, these words can be particularly devastating. The five-year survival rate can be a little as 6 percent. The top-of-mind question becomes, "Which treatment or clinical trial will work for me?"
Ahead of World TB Day, US Food and Drug Administration Commissioner Margaret Hamburg helped public and private sector partners launch a new collaboration to significantly accelerate the development of combination treatments for tuberculosis — and replace an almost 50-year-old drug regimen. Created by the Global Alliance for TB Drug Development, the Critical Path Institute, and the Bill & Melinda Gates Foundation, the initiative could potentially reduce the time it takes to introduce new combination TB treatments from as much as a quarter century to as few as six years.
Twist Bioscience today announced that it raised $26 million in a Series B financing to commercialize the company's semiconductor-based synthetic gene manufacturing process.
The University of North Carolina at Chapel Hill has received a seven-year, more than $40 million award from the National Institutes of Health for a clinical trials unit that will implement the scientific agendas of five NIH networks devoted to HIV/AIDS treatment, prevention, and cure research.
› Verified 9 days ago
Parkwood Health Care Facility Location: 3301 Stadium Drive, Phenix City, Alabama 36867 Phone: (334) 297-0237 | |
Phenix City Health Care, Inc Location: 3900 Lakewood Drive, Phenix City, Alabama 36867 Phone: (334) 298-8247 | |
Canterbury Health Care Facility Location: 1720 Knowles Road, Phenix City, Alabama 36869 Phone: (334) 291-0485 |